More on MNOV
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.28 |
|
|||
| Open | $1.26 | ||||
| 52 Wk High | $10.16 | ||||
| 52 Wk Low | $2.91 | ||||
| Day High | $1.26 | ||||
| Day Low | $1.23 | ||||
| P/E | N/A | ||||
| EPS | $-0.41 | ||||
| Volume | 103,460 | ||||
- MediciNova receives patent allowance for glioblastoma combination therapy
- MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
- MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
- Form 10-Q MEDICINOVA INC For: Mar 31
- Form ARS MEDICINOVA INC For: Dec 31
- Form DEFA14A MEDICINOVA INC
- Form DEF 14A MEDICINOVA INC For: Jun 23
- New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
- Form PRER14A MEDICINOVA INC
- Form PRE 14A MEDICINOVA INC For: Jun 23
Entities mentioned with MNOV
- FDA | View Related Stories »
- Ladenburg Thalmann Financial Services | View Related Stories »
- Earnings | View Related Stories »
- Pre Market Movers | View Related Stories »
- S3 | View Related Stories »
- Definitive Agreement | View Related Stories »
- B. Riley | View Related Stories »
- Pre-Open Losers | View Related Stories »
- Show More...
